Titre :

Reliability of QuantiFERON®-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.

Auteur(s) :

Sermet, Kevin [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Goeminne, Céline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hantz, Sébastien [Auteur]
Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques [RESINFIT]
Assaf, Ady [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Faure, Emmanuel [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Lazrek, Mouna [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Faure, Karine [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Alain, Sophie [Auteur]
Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques [RESINFIT]
Vuotto, Fanny [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]

Titre de la revue :

Clinical Transplantation

Pagination :

e15109

Éditeur :

Wiley

Date de publication :

2023-08-29

ISSN :

0902-0063

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BackgroundRecurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains ...
Lire la suite >BackgroundRecurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®-CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.MethodsThis observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T-cell-mediated CMV immunity QuantiFERON®-CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.ResultsAmong the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®-CMV test. The duration of secondary prophylaxis was similar regardless of QF-CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus-containing immunosuppressive regimen.ConclusionIn the population of heart transplant recipients, most of whom received ATG-based induction, the QuantiFERON®-CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell-mediated immunity tests and strategies in this specific population, including everolimus-containing regimens, may help predict and manage CMV recurrence.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL